The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma.
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Juan Manuel Sepulveda Sanchez
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - BMS; Cantex Pharmaceuticals; CeCaVa; Novocure; Servier
Speakers' Bureau - SERVIER
Research Funding - Cantex Pharmaceuticals (Inst); IDP Pharmaceuticals (Inst); Pfizer (Inst); Tilray (Inst); Varsity Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Olatunji Alese
No Relationships to Disclose
 
Georgia Anguera
Consulting or Advisory Role - Ipsen; Merck; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Ipsen; Johnson & Johnson/Janssen; Merck; MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb Spain; Ipsen; Johnson & Johnson/Janssen; Merck; MSD Oncology
 
Chandrikha Chandrasekharan
No Relationships to Disclose
 
Sant Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Melissa Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Merck
 
Maen Abdelrahim
Consulting or Advisory Role - AstraZeneca; Ipsen
 
John Villano
Consulting or Advisory Role - SERVIER
 
Bo Zhang
Employment - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
Honoraria - HUTCHMED
 
Yukang Wang
Employment - HUTCHMED
Honoraria - HUTCHMED
 
Xiuya Yu
Employment - HUTCHMED
Honoraria - HUTCHMED
 
Zeyu Zhong
Employment - HUTCHMED
Honoraria - HUTCHMED
 
Xian Luo
Employment - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
Honoraria - HUTCHMED
 
Songhua Fan
Employment - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
Honoraria - HUTCHMED
 
Michael Shi
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
Honoraria - HUTCHMED
 
Weiguo Su
Employment - HUTCHMED
Leadership - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
Honoraria - HUTCHMED
 
Maria Vieito Villar
Consulting or Advisory Role - BMS
Speakers' Bureau - Novocure
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Novartis (Inst); Roche; Roche/Genentech (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Travel, Accommodations, Expenses - Roche
Other Relationship - BMS GmbH & Co. KG (Inst); Debiopharm Group (Inst); HUTCHMED (Inst); Incyte (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst)